ConductScience.org, home
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
API referenceFor AI assistants

Trial · NCT05361668

Results by group52

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 52

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)40 mg PaltusotineTreatment-Emergent Adverse Events (TEAE)16participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)80 mg PaltusotineTreatment-Emergent Adverse Events (TEAE)15participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)40 mg PaltusotineTEAE Related to CS Symptoms10participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)80 mg PaltusotineTEAE Related to CS Symptoms9participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)40 mg PaltusotineHighest Severity of TEAE: Severe TEAE3participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)80 mg PaltusotineHighest Severity of TEAE: Severe TEAE1participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)40 mg PaltusotineHighest Severity of TEAE: Moderate TEAE6participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)80 mg PaltusotineHighest Severity of TEAE: Moderate TEAE7participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)40 mg PaltusotineHighest Severity of TEAE: Mild TEAE7participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)80 mg PaltusotineHighest Severity of TEAE: Mild TEAE7participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)40 mg PaltusotineSerious TEAE2participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)80 mg PaltusotineSerious TEAE2participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)40 mg PaltusotineTreatment Related TEAE10participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)80 mg PaltusotineTreatment Related TEAE13participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)40 mg PaltusotineTreatment Related Serious TEAE0participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)80 mg PaltusotineTreatment Related Serious TEAE0participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)40 mg PaltusotineTEAE Leading to Study Discontinuation1participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)80 mg PaltusotineTEAE Leading to Study Discontinuation1participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)40 mg PaltusotineTEAE Leading to Actions Taken with Study Treatment: Dose Increased3participants
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)80 mg PaltusotineTEAE Leading to Actions Taken with Study Treatment: Dose Increased1participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05361668/results

API referenceFor AI assistants